I am pleased to announce the launch of Bioengineering & Translational Medicine, a new journal from AIChE and SBE, and our publishing partner, Wiley. This new journal will focus on ways Chemical and Biological Engineering drive innovations and solutions that impact clinical practice and commercial healthcare products. The journal will also highlight scientific and technical breakthroughs currently in the process of clinical and commercial translation.
Like me, in recent years, you’ve likely seen reports in the literature about a large number of engineering advances that claim potential application in clinical medicine. Converting these discoveries into useful clinical products, however, is a major challenge. It requires attention to issues such as safety, manufacturability, regulatory hurdles, cost, and patient acceptance—issues that are not typically considered in academic research. Clinical translation also often requires simultaneous consideration of commercial translation, with the team and the resources required for clinical translation often also needed for any commercial translation. This interplay brings its own set of challenges. Bioengineering & Translational Medicine welcomes manuscripts that provide new insights into translational hurdles, as well as examples of technologies that have demonstrated excellent progress toward clinical or commercial translation. We also welcome manuscripts that provide new scientific insights and fundamental advances that facilitate translation.
Bioengineering & Translational Medicine also invites contributions on topics including, but not limited to, drug delivery, drug discovery, tissue engineering, synthetic biology, gene therapy, computational modeling and bioinformatics, among others. A more comprehensive list of topics can be found in the journal’s statement of scope.
To researchers who are active, or aspiring to be active, in clinical and commercial translation of biological technologies, I say “this is your journal.” With a stellar advisory board behind us, we are poised for an exciting, quick, and successful launch. We look forward to receiving your manuscripts. We promise a rapid and fair review and fast publication. We also welcome your suggestions and comments on ways we can make the journal better serve your needs.
Thank you for sharing our enthusiasm about Bioengineering & Translational Medicine and I look forward to working with you.
Interview: Samir Mitragotri Discusses New Journal
About the Journal
Bioengineering & Translational Medicine is an official quarterly, peer-reviewed, online, open access journal of the American Institute of Chemical Engineers (AIChE) and its technological community, the Society for Biological Engineering (SBE), published on our behalf by John Wiley & Sons. The inaugural issue will debut in 2016. The journal web page on the Wiley Online Library is online at http://bioengtransmed.com.
Bioengineering & Translational Medicine is focused on the fundamental ways chemical and biological engineering approaches drive and provide innovative technologies and solutions that impact clinical practice and/or commercial healthcare products. The journal includes research reports, reviews, and rapid communications with a focus on biomolecular engineering advances.
Topics covered in Bioengineering & Translational Medicine include:
- Drug delivery
- Drug discovery and development
- Tissue engineering
- Chemical engineering-based bioprocessing
- Synthetic biology
- Organoids and organ-mimetic systems
- Stem cell therapies
- Gene therapies
- Patient-targeted therapies
- Medical devices
- Regenerative medicine
- Implant/patient interface
- Computational modeling
Chemical engineers; biological engineers, biomolecular engineers, biomedical engineers, and other engineers and professionals with specific interests in translational medicine, biotechnology, and biochemical and biomolecular engineering; physicians and other healthcare researchers and professionals
Editorial Advisory Board
- Kristi Anseth, University of Colorado Boulder
- Mark Davis, California Institute of Technology
- Michael Deem, Rice University
- Francis J. Doyle III, Harvard University
- George Georgiou, University of Texas, Austin
- Linda Griffith, Massachusetts Institute of Technology
- Paula Hammond, Massachusetts Institute of Technology
- Justin Hanes, Johns Hopkins University
- Ravi Kane, Georgia Institute of Technology
- Ali Khademhosseini, Harvard University
- Chaitan Khosla, Stanford University
- Richard Korsmeyer, Pfizer
- Cato Laurencin, University of Connecticut
- Raghunath A. Mashelkar, CSIR-National Chemical Laboratory, India
- Antonios Mikos, Rice University
- Nicholas Peppas, University of Texas, Austin
- Mark Prausnitz, Georgia Institute of Technology
- W. Mark Saltzman, Yale University
- David Schaffer, University of California, Berkeley
- Gregory Stephanopoulos, Massachusetts Institute of Technology
- David Tirrell, California Institute of Technology
- Matthew Tirrell, University of Chicago
- Subbu Venkatraman, Nanyang Technological University, Singapore
- Jackie Ying, A*-STAR, Institute of Bioengineering and Nanotechnology